Long COVID and COVID-19-associated cystitis (CAC)
| Autor: | Michael B. Chancellor, Dragana Komnenov, Ryan Timar, Laura E. Lamb, Melissa Wills, Steve M. Lucas, Nivedita Dhar, Sorabh Dhar |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Nephrology
medicine.medical_specialty Future studies Long COVID Coronavirus disease 2019 (COVID-19) Urinary symptoms Urology - Original Paper business.industry SARS-CoV-2 Urology Bladder Overactive bladder COVID-19-associated cystitis COVID-19 Context (language use) Disease medicine.disease Internal medicine Medicine business Genitourinary symptoms |
| Zdroj: | International Urology and Nephrology |
| ISSN: | 1573-2584 0301-1623 |
| Popis: | Purpose There is scarce literature regarding genitourinary symptoms in COVID-19, especially post-acute disease otherwise known as Long COVID. We identified recovered COVID-19 patients presenting with new or worsening overactive bladder symptoms, known as COVID-19-associated cystitis (CAC). Methods We used the American Urological Association Urology Care Foundation Overactive Bladder (OAB) Assessment Tool to screen COVID-19 recovered patients presenting with urological complaints at our urban-located institution from 5/22/2020 to 12/31/2020. Patients 10–14 weeks post-discharge responded to 5 symptom and 4 quality-of-life (QoL) questions. We reported median symptom scores, as well as QoL scores, based on new or worsening urinary symptoms, and by sex. Results We identified 350 patients with de novo or worsening OAB symptoms 10–14 weeks after hospitalization with COVID-19. The median total OAB symptom score in both men and women was 18. The median total QoL score for both men and women was 19. Patients with worsening OAB symptoms had a median pre-COVID-19 symptom score of 8 (4–10) compared to post-COVID-19 median symptom score of 19 (17–21). Median age was 64.5 (range 47–82). Median hospital length-of-stay was 10 days (range 5–30). Conclusion We report survey-based results of patients suffering from new or worsening OAB symptoms months after their hospitalization from COVID-19. Future studies with larger sample sizes and more extensive testing will hopefully elucidate the specific pathophysiology of OAB symptoms in the context of long COVID so urologists can timely and appropriately treat their patients. Supplementary Information The online version contains supplementary material available at 10.1007/s11255-021-03030-2. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink